Dubai, United Arab Emirates - April 1, 2013: After completing its registration and licensing in the Ministry of Health, a new medicine for endometriosis was announced yesterday during the two-day 'Obs-Gyne Exhibition & Congress' that was held on March 31 and April 2, 2013 to discuss the issue, while the only treatment that has always been given to patients with endometriosis complains is the pain relievers.
Prominent speakers and experts took part in the meet and presented their papers, researches and viewpoints.
Dr. Nicholas Leyland, Professor and Chair of Obstetrics and Gynaecology, McMaster University, Ontario, Canada, presented his paper on 'Abnormal Uterine Bleeding (AUB) Management: SOGC Guidelines'. He said, "Some of the symptoms of endometriosis include pain during period, pre-menstrual pain, which is more severe than the natural menstrual pain and the pain severity does not necessarily involve the large size of endometriosis, pain during and after sexual intercourse, severe acute or abnormal uterine bleeding, and infertility."
Dr. Leyland added that there are other symptoms, such as fatigue, menstrual cramps (Dysmenorrhoea), lower back pain, and diarrhoea or constipation, as well as some other menstruation-associated intestinal disorders.
He said, "There are, however, some cases that do not suffer from any symptoms."
Speaking on the occasion, Dr. Muna Tahlak, Consultant Obstetrics and Gynaecology, Latifa Hospital, Dubai, said, "The new medicine would significantly reduce the pain associated with the disease. Medical specialists estimate that the number of UAE Nationals and residents, who suffer from symptoms of this disease, has reached 100,000 mark by now across the country."
She added that the clinical trials that have been made involving women living with endometriosis for up to 15 months at a low dose found that the new drug that contains the active ingredient, Dienogest, can effectively reduce the pain and is as effective in treating the disease as a gonadotropin-releasing hormone analogue (GnRH-analogue).
In addition, clinical studies have also shown that the new drug has no serious side effects of the decrease in the levels of estrogen in the body, such as low bone mineral density, and other menopausal symptoms associated with the GnRH-analogue treatment, such as hot flushes and vaginal dryness, Dr. Tahlak said.
She further added that the report of patients, treated with the new drug in clinical trials, pointed to a continuous improvement in alleviating the pain associated with endometriosis over 15 months.
Dr. Bassem Abdullah, Country Division Head - Gulf, and spokesperson of Bayer HealthCare Middle East, said, "We are committed to improving the health and well-being of women and their families in general, through researching and developing new treatment options for diseases afflicting women folk."
He added, "Doctors and patients concerned with the disease feel that the introduction of the new endometriosis treatment to global and local markets marks a considerable step forward in treating this chronic, debilitating disease."
About Endometriosis:
Endometriosis is a chronic disease where tissue that resembles the lining of the womb (uterus) is found elsewhere in the body. This tissue forms endometrial lesions which are most often found on the ovaries and all other organs within a woman's pelvis. In very rare cases they can be found in the lungs and even the brain. To learn more about Endometriosis, please visit the website: www.endometriosisuae.com
About Dienogest:
Dienogest 2mg Is a new low-dose treatment to reduce the painful symptoms of endometriosis. Dienogest contains a progestin called dienogest which is particularly suited to effectively treat endometriosis and to relieve pain. Progestins (sometimes called progestogens) are the chemically synthesised version of the natural hormone progesterone which plays an important role in the menstrual cycle and pregnancy.
About Etisal Event Management:
Etisal Event Management is a leading creative services firm that provides effective, award-winning public relations and events management services to clients seeking to carve out a niche in the competitive world of business. It specializes exclusively in corporate communications, event management, public relations, conferences and exhibitions. For more information, please visit our website at www.etisal.ae
Contact:
Mr. Maurice Ferando 050-7394081
ETISAL Event Management
Phone: 04 222 54 25
Fax: 04 224 06 56
E-mail: maurice@etisal.ae
Address: Radisson BLU Hotel, Deira, Dubai - UAE
Website: www.etisal.ae
© Press Release 2013
